Antleron is an R&D company specialized in bespoke cell and gene therapy product and bioprocess modelling, wet lab research & development, and clinical & industrial translation. Antleron’s hybrid bioprocess development platform enables faster, more affordable, and more equitable delivery of cell and gene therapies to patients by integrating scalable, closed and automated bioreactors with AI-driven digital-twins. From discovery to process development and CMC, Antleron’s smart scale-down model service combines custom, lab-scale, modular bioreactors with its Nexus-driven digital twin platform to predict, develop and optimize clinical-scale bioprocesses and manufacturing systems. Antleron’s CellGuide® fixed-bed upstream bioreactor platform completes its smart scale-down model offering by enabling improved quality, consistency and scalability from lab to patient for bespoke therapies.
| Website | http://www.antleron.com |
| Employees | 22 (16 on RocketReach) |
| Founded | 2014 |
| Phone | +32 16 75 13 71 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+9 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Regenerative Medicine, Advanced Therapies, Medical Devices, Biomaterials, Cell Therapy, Biologics, 3d Bioprinting, Tissue Engineering, Drug Delivery, Biotechnology, Pharmaceutical Research, Medical Technology, Healthcare Innovation, Precision Medicine, Therapeutic Innovation, Biomanufacturing, Stem Cell Therapy, Cell Engineering, Clinical Trials |
| Competitors | Organogenesis, bluebird bio, Fate Therapeutics Inc, AVITA Medical, Athersys, Tissue Regenix Group, TissUse GmbH, Lorem Cytori USA, Inc, Sierra Oncology, RepliCel Life Sciences Inc. +35 more (view full list) |
Looking for a particular Antleron employee's phone or email?
Jan Schrooten is the Co-Founder and CEO of Antleron.
16 people are employed at Antleron.